Insulins for the long term management of diabetes mellitus in dogs: a review.

Canine Med Genet. February 2022;9(1):1.

Robert E Shiel¹, Carmel T Mooney²

¹ School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland. robert.shiel@ucd.ie.; ² School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

Abstract

The year 2021 marked the centenary of the isolation of a therapeutic form of insulin and its successful use in dogs. This was a landmark moment that subsequently and rapidly led to the commercial manufacture of insulin for use in humans. The impact of insulin was almost miraculous as those destined to die from their diabetes mellitus returned to life. Over the past 100 years, insulin formulations have been modified to attempt to provide a predictable and prolonged duration of action while avoiding the development of hypoglycaemia. This has led to an ever-growing variety of insulin types in human medicine, many of which have subsequently been used in dogs. The purpose of this review article is to provide an overview of available insulin types and their application to the chronic management of canine diabetes mellitus.

Keywords

Diabetes mellitus; Dogs; Insulin; Pharmacology;

Article Tools:

Medline

Email to me

Comments:

Erratum In Canine Med Genet. 2022 Mar 4;9(1):3. doi: 10.1186/s40575-022-00115-8

Archives Highlights:

Resolution of egg binding is possible in most client-owned parrots when multiple treatment strategies are considered.
Of the 150 events that had complete follow-up, 109 (72.7%) resulted in a successful outcome. A successful outcome was observed in 44 of 133 events (33.1%) that were initially managed medically without resorting to additional treatment strategies, in 31 events (86.1%) managed with mechanical assistance, in 20 events (60.6%) managed surgically, and in 12 events (85.7%) managed with ovocentesis.

Factors Associated with Medication Noncompliance in Dogs in New Zealand.
Medication noncompliance was recorded for 47% (71/151) of owners. Increasing dog age was associated with better owner compliance. Forty-seven percent (71/151) of owners reported that "nobody" showed them how to administer the medication. One-third of dog owners (47/151) reported challenges in medicating their pets. The most common reason cited by clients reporting challenges was a resistant pet.

Effective treatment with afoxolaner (NexGard) of Trixacarus caviae in a pet guinea pig.
The animal was treated with a single oral dose of 2.50 mg/kg afoxolaner, and the lesions, presence/absence of mites, and intensity of pruritus were evaluated periodically until 2 months post-treatment. A week after the medication, the lesions were milder, but pruritus was still present and was attributed to the healing process. Further examinations showed significant improvement with the complete remission of clinical signs and no mites at the microscopic examination after 4 weeks.

Owner survey suggests cats may be undertreated for pain compared to dogs after an elective ovariohysterectomy or orchiectomy.
Analgesics were prescribed for 19 of 162 (12%) pets: 14 of 88 (16%) dogs and 5 of 74 (6.7%) cats. There was no difference in the prescription of analgesics between dogs and cats after ovariohysterectomy or orchiectomy. 15 of 19 owners reported their compliance in administering analgesics at 78.9%. Owners' subjective assessments showed that 24 of 86 (28%) dogs and 12 of 68 (17%) cats appeared painful at home.

Recovery of ambulation in small, nonbrachycephalic dogs after conservative management of acute thoracolumbar disk extrusion.
Forty-nine of fifty-one (96%) of deep pain-positive and 10/21 (48%) of deep pain-negative dogs recovered ambulation within the 12-week period. The median time to ambulation was 11 and 25 days for deep pain-positive and -negative dogs, respectively. Reduction in spinal cord compression varied among individuals from minimal to complete and apparently was unrelated to the recovery of ambulation.